Unsolved Issues on Beneficial Effects of Combination Therapy With Sotatercept in Pulmonary Arterial Hypertension

Hoeper et  al. [1] reported impressive results from the multicentre, phase 3 trial “STELLAR” (A Study of Sotatercept in Combination With Background Therapy for the Treatment of Pulmonary Arterial Hypertension), which have been recently published in The New England Journal of Medicine. Of note, a combinat ion therapy with sotatercept added to the standard therapy significantly improved exercise capacity in patients with pulmonary arterial hypertension (PAH) when compared with placebo, resulting in improved 6-minute walking distance, decreased pulmonary vascular resistance and N-terminal B-type natriu retic peptide level, and improved functional class.
Source: Heart, Lung and Circulation - Category: Cardiology Authors: Tags: Commentary Source Type: research